Novartis AG;The Trustees of the University of Pennsylvania
发明人:
申请号：
EP16881286.5
公开号：
EP3397756A4
申请日:
2016.12.30
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
